From its initial use in the treatment of type 2 diabetes to its expansion to 12 indications such as obesity, cardiovascular disease, chronic kidney disease, and metabolic dysfunction related fatty liver disease (MASLD), the annual sales of GLP-1 drugs exceeded 100 billion dollars, and its research and development funding reached a historical peak of 21.72 million dollars in 2025
The experimental shot helped people lose almost 11% of their body weight -- less than the currently available injections Wegovy and Zepbound
Owing to the rising disposable incomes, patients are able to afford advanced diabetes and obesity treatments, contributing to the rapid growth of the market in the country
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
